KRAS mutation‐positive non‐small cell lung cancer (NSCLC) was associated with an increased risk of VTE (OR: 2.67) compared to NSCLC patients without KRAS mutation [12], and ROS1 or ALK fusion‐positive NSCLC had a higher incidence of thromboembolisms than in EGFR mutated NSCLC [13]. This evidence concerns the gene KRAS and lung cancer.